{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:49:47Z","timestamp":1791884987561,"version":"4.3.4"},"reference-count":74,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["advanced.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advanced Materials"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Thirty years after the approval of Doxil, nanomedicine has generated extraordinary scientific output and enabled therapeutic modalities that would otherwise have remained impractical. Its clinical translation, however, remains more limited than the scale and sophistication of the field might suggest, particularly when targeted systemic delivery is required. In the recent past, others have highlighted those limitations, however, what concerns us is that some of the assumptions that constrained earlier generations of nanomedicines are now re\u2010emerging in AAV\u2010based gene therapy and in vivo CAR\u2010T platforms. More precise payloads do not make delivery more precise, nor do viral vectors escape the biological barriers encountered by synthetic nanoparticles. In this Perspective, we revisit the liver paradox, the distinction between organ accumulation and functional delivery, the protein corona and the promise of biomimetic systems. Our intention is not to add another catalogue of limitations, but to ask what should change. We argue that the next phase of drug delivery should be less focused on adding complexity to the carrier and more committed to quantifying its biological journey.<\/jats:p>","DOI":"10.1002\/adma.75364","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:40:30Z","timestamp":1791884430000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanoparticles and Medicine Thirty Years After the First FDA Approval: Time to Renew the Vows"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-0892","authenticated-orcid":false,"given":"Roberto","family":"Molinaro","sequence":"first","affiliation":[{"name":"XGEN Venture SGR S.p.A.  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-2571","authenticated-orcid":false,"given":"Claudia","family":"Corbo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery University of Milano\u2010Bicocca Monza Italy"},{"name":"IRCCS Istituto Ortopedico Galeazzi  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020"},{"key":"e_1_2_7_3_1","unstructured":"Johnson & JohnsonJohnson Announces Collaboration With Sail Biomedicines to Advance In Vivo CAR\u2010T Programs and Transform Autoimmune Disease Through Immune Reset. July 29 2026 https:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/johnson\u2010johnson\u2010announces\u2010collaboration\u2010with\u2010sail\u2010biomedicines\u2010to\u2010advance\u2010in\u2010vivo\u2010car\u2010t\u2010programs\u2010and\u2010transform\u2010autoimmune\u2010disease\u2010through\u2010immune\u2010reset."},{"key":"e_1_2_7_4_1","unstructured":"E. Lilly and Company.Lilly to Acquire Kelonia Therapeutics to Advance In Vivo CAR\u2010T Cell Therapies. April 20 2026 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lilly\u2010acquire\u2010kelonia\u2010therapeutics\u2010advance\u2010vivo\u2010car\u2010t\u2010cell."},{"key":"e_1_2_7_5_1","unstructured":"E. Lilly and Company.Lilly to Acquire Orna Therapeutics to Advance Cell Therapies. February 9 2026 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lilly\u2010acquire\u2010orna\u2010therapeutics\u2010advance\u2010cell\u2010therapies."},{"key":"e_1_2_7_6_1","unstructured":"T\u2010CURX and Pantherna Therapeutic.T\u2010CURX Acquires Pantherna Therapeutics to Accelerate Clinical Translation of Its Non\u2010viral In Vivo CAR\u2010T Strategies. June 1 2026 https:\/\/www.pantherna\u2010therapeutics.com\/t\u2010curx_acquires_pantherna_therapeutics_to_accelerate_clinical_translation_of_its_non\u2010viral_in_vivo_car\u2010t_strategies\/."},{"key":"e_1_2_7_7_1","unstructured":"LEO Pharma.LEO Pharma Bolsters Rare Skin Disease Focus Through Acquisition of Replay Gene Therapy Platform. April 30 2026 https:\/\/www.leo\u2010pharma.com\/media\u2010center\/news\/2026\u2010leo\u2010pharma\u2010acquires\u2010replay."},{"key":"e_1_2_7_8_1","unstructured":"MeiraGTx.MeiraGTx Enters Into Strategic Collaboration With Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology. November 10 2025 https:\/\/investors.meiragtx.com\/news\u2010releases\/news\u2010release\u2010details\/meiragtx\u2010enters\u2010strategic\u2010collaboration\u2010eli\u2010lilly\u2010and\u2010company\/."},{"key":"e_1_2_7_9_1","unstructured":"Gilead Sciences.Gilead Sciences Announces Third Quarter 2025 Financial Results. October 30 2025 https:\/\/www.gilead.com\/news\/news\u2010details\/2025\/gilead\u2010sciences\u2010announces\u2010third\u2010quarter\u20102025\u2010financial\u2010results."},{"key":"e_1_2_7_10_1","unstructured":"Bristol Myers Squibb.Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics October 10 2025 https:\/\/news.bms.com\/news\/details\/2025\/Bristol\u2010Myers\u2010Squibb\u2010Strengthens\u2010and\u2010Diversifies\u2010Cell\u2010Therapy\u2010Portfolio\u2010with\u2010Acquisition\u2010of\u2010Orbital\u2010Therapeutics\/default.aspx."},{"key":"e_1_2_7_11_1","unstructured":"Gilead Sciences\/Kite.Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform. August 21 2025 https:\/\/www.gilead.com\/news\/news\u2010details\/2025\/kite\u2010to\u2010acquire\u2010interius\u2010biotherapeutics\u2010to\u2010advance\u2010in\u2010vivo\u2010platform."},{"key":"e_1_2_7_12_1","unstructured":"AbbVie.AbbVie to Acquire Capstan Therapeutics Further Strengthening Commitment to Transforming Patient Care in Immunology. June 30 2025 https:\/\/news.abbvie.com\/2025\u201006\u201030\u2010AbbVie\u2010to\u2010Acquire\u2010Capstan\u2010Therapeutics%2C\u2010Further\u2010Strengthening\u2010Commitment\u2010to\u2010Transforming\u2010Patient\u2010Care\u2010in\u2010Immunology."},{"key":"e_1_2_7_13_1","unstructured":"AstraZeneca.AstraZeneca to Acquire EsoBiotec to Advance Cell Therapy Ambition. March 17 2025 https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2025\/astrazeneca\u2010to\u2010acquire\u2010esobiotec.html."},{"key":"e_1_2_7_14_1","unstructured":"Sangamo Therapeutics.Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System. April 3 2025 https:\/\/investor.sangamo.com\/news\u2010releases\/news\u2010release\u2010details\/sangamo\u2010therapeutics\u2010announces\u2010capsid\u2010license\u2010agreement\u2010lilly."},{"key":"e_1_2_7_15_1","unstructured":"JCR Pharmaceuticals.JCR Pharmaceuticals Enters License Agreement With Alexion for Proprietary JUST\u2010AAV Capsids to be Used in the Development of Genomic Medicines. July 8 2025 https:\/\/jcrpharm.com\/jcr\u2010pharmaceuticals\u2010enters\u2010license\u2010agreement\u2010with\u2010alexion\u2010for\u2010proprietary\u2010just\u2010aav\u2010capsids\u2010to\u2010be\u2010used\u2010in\u2010the\u2010development\u2010of\u2010genomic\u2010medicines\/."},{"key":"e_1_2_7_16_1","unstructured":"Astellas Pharma and Sangamo Therapeutics.Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases. December 19 2024 https:\/\/newsroom.astellas.com\/2024\u201012\u201019\u2010Astellas\u2010and\u2010Sangamo\u2010Therapeutics\u2010Announce\u2010Capsid\u2010License\u2010Agreement\u2010to\u2010Deliver\u2010Genomic\u2010Medicines\u2010for\u2010Neurological\u2010Diseases."},{"key":"e_1_2_7_17_1","unstructured":"Novartis.Addressing Unmet Needs for Inherited Neuromuscular Diseases: Acquisition of Kate Therapeutics. November 21 2024 https:\/\/www.novartis.com\/stories\/addressing\u2010unmet\u2010needs\u2010inherited\u2010neuromuscular\u2010diseases."},{"key":"e_1_2_7_18_1","unstructured":"Astellas Pharma and AviadoBio.Exclusive Option and License Agreement for AAV Gene Therapy AVB\u2010101. October 8 2024 https:\/\/aviadobio.com\/astellas\u2010and\u2010aviadobio\u2010announce\u2010exclusive\u2010option\u2010and\u2010license\u2010agreement\u2010for\u2010gene\u2010therapy\u2010avb\u2010101\u2010targeting\u2010frontotemporal\u2010dementia\u2010and\u2010other\u2010indications\/."},{"key":"e_1_2_7_19_1","unstructured":"GenEdit.GenEdit Announces Multiyear Collaboration and License Agreement With Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease. January 23 2024 https:\/\/www.businesswire.com\/news\/home\/20240123633144\/en\/."},{"key":"e_1_2_7_20_1","unstructured":"Voyager Therapeutics.Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration With Novartis to Advance Novel Gene Therapies. January 2 2024 https:\/\/ir.voyagertherapeutics.com\/news\u2010releases\/news\u2010release\u2010details\/voyager\u2010therapeutics\u2010enters\u2010capsid\u2010license\u2010agreement\u2010and."},{"key":"e_1_2_7_21_1","unstructured":"AbbVie and Umoja Biopharma.Strategic Collaboration to Develop Novel In\u2010situ CAR\u2010T Cell Therapies. January 4 2024 https:\/\/news.abbvie.com\/2024\u201001\u201004\u2010AbbVie\u2010and\u2010Umoja\u2010Biopharma\u2010Announce\u2010Strategic\u2010Collaboration\u2010to\u2010Develop\u2010Novel\u2010In\u2010Situ\u2010CAR\u2010T\u2010Cell\u2010Therapies."},{"key":"e_1_2_7_22_1","unstructured":"Serina Therapeutics.Serina Therapeutics Announces POZ Polymer Technology License Agreement With Pfizer. November 17 2023 https:\/\/www.biospace.com\/serina\u2010therapeutics\u2010announces\u2010poz\u2010polymer\u2010technology\u2010license\u2010agreement\u2010with\u2010pfizer."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.937"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578\u2010021\u201000358\u20100"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/nn404501g"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2012.237"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.14"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41563\u2010019\u20100566\u20102"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2012.207"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.03.006"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412309"},{"key":"e_1_2_7_34_1","unstructured":"Intellia Therapeutics Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR\u2010CM https:\/\/ir.intelliatx.com\/node\/12526\/html March 2 2026."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202519037"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202521487"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmat4718"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja505986a"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx960"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913147"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021712"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.07.025"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00037\u20106"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41565\u2010022\u201001146\u20109"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202100887"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003\u2010021\u201001728\u20108"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201902333"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmat4644"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202513548"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7NR04734G"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9NR04253A"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201702749"},{"key":"e_1_2_7_55_1","unstructured":"U.S. Food and Drug Administration \u201cFDA Approves New Safety Warning and Revised Indication That Limits Use for Elevidys Following Reports of Fatal Liver Injury \u201dhttps:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010new\u2010safety\u2010warning\u2010and\u2010revised\u2010indication\u2010limits\u2010use\u2010elevidys\u2010following\u2010reports\u2010fatal November 14 2025."},{"key":"e_1_2_7_56_1","unstructured":"Pfizer.Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys With Duchenne Muscular Dystrophy. June 12 2024 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/pfizer\u2010provides\u2010update\u2010phase\u20103\u2010study\u2010investigational\u2010gene."},{"key":"e_1_2_7_57_1","doi-asserted-by":"crossref","unstructured":"Pfizer.Q3 2024 Earnings Charts. October 29 2024 https:\/\/investors.pfizer.com\/files\/doc_financials\/2024\/q3\/Q3\u20102024\u2010Earnings\u2010Charts_FINAL.pdf.","DOI":"10.1016\/j.fopow.2024.02.009"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.9.3410"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.14164"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131660"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.10.061"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2018.11.002"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9NR08784B"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1307152110"},{"key":"e_1_2_7_65_1","unstructured":"U.S. Food and Drug Administration.FDA approves drug to treat neurologic manifestations of Hunter syndrome. March 25 2026 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010drug\u2010treat\u2010neurologic\u2010manifestations\u2010hunter\u2010syndrome."},{"key":"e_1_2_7_66_1","unstructured":"Dyne Therapeutics.Dyne Therapeutics announces U.S. FDA Acceptance of Biologics License Application for z\u2010rostudirsen in exon 51 Duchenne Muscular Dystrophy. July 20 2026 https:\/\/investors.dyne\u2010tx.com\/news\u2010releases\/news\u2010release\u2010details\/dyne\u2010therapeutics\u2010announces\u2010us\u2010fda\u2010acceptance\u2010biologics\u2010license\/."},{"key":"e_1_2_7_67_1","unstructured":"Novartis.Novartis Provides Update on Delpacibart Etedesiran (del\u2010desiran) Phase III HARBOR Study for the Treatment of Myotonic Dystrophy Type 1. September 8 2026 https:\/\/www.novartis.com\/us\u2010en\/news\/media\u2010releases\/novartis\u2010provides\u2010update\u2010delpacibart\u2010etedesiran\u2010del\u2010desiran\u2010phase\u2010iii\u2010harbor\u2010study\u2010treatment\u2010myotonic\u2010dystrophy\u2010type\u20101\u2010dm1."},{"key":"e_1_2_7_68_1","unstructured":"Roche.Roche Presents New Data in Alzheimer's Disease From Across its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC. July 7 2026 https:\/\/www.roche.com\/media\/releases\/med\u2010cor\u20102026\u201007\u201007."},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010017\u201011220\u20101"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adv8761"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010025\u201063726\u20102"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109256118"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.26599\/NR.2026.94908571"},{"key":"e_1_2_7_74_1","unstructured":"ReC Therapeutics.The Next Generation of Genetic Medicine Delivery: SORT LNP Platform. August 6 2026 https:\/\/recodetx.com\/science\/."},{"key":"e_1_2_7_75_1","unstructured":"METiS Therapeutics.AI\u2010Enabled Drug Discovery and Delivery Platform. August 6 2026 https:\/\/www.metistx.com\/."}],"container-title":["Advanced Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/adma.75364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/adma.75364","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/adma.75364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:40:35Z","timestamp":1791884435000},"score":1,"resource":{"primary":{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/10.1002\/adma.75364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":74,"alternative-id":["10.1002\/adma.75364"],"URL":"https:\/\/doi.org\/10.1002\/adma.75364","archive":["Portico"],"relation":{},"ISSN":["0935-9648","1521-4095"],"issn-type":[{"value":"0935-9648","type":"print"},{"value":"1521-4095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2026-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e75364"}}